1020

In this month’s issue of The Medicine Maker, we sit down with Richard M. Johnson, President, and Chief Executive Officer of the Parenteral Drug Association, who shares some career-defining experiences with us. In Business, we examine the state of US pharma and what the upcoming election could mean for the industry. Kiran Mazumdar-Shaw also shares the story behind Biocon’s biopharmaceutical success. In NextGen, we ask Duncan Peyton, Chief Executive Officer at 4D pharma about the importance of live biotherapeutics, and in our cover feature, we explore the challenges and opportunities that await African pharma.

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

I want to receive an alert when the next issue is available online

Articles featured in this issue

Manufacture Quality & Compliance

Animal Alternatives

09/14/2020 | Maryam Mahdi

How can we reduce animal testing in quality control procedures?

Manufacture Technology and Equipment

Top Tier Innovation

10/13/2020

Nominate the top pharmaceutical technologies in our 2020 Innovation Awards.

Manufacture Formulation

The Drug Dose Gender Gap

09/22/2020 | Maryam Mahdi

How can we achieve gender parity in drug dosing?

Manufacture Vaccines

Don’t Exclude the Aged

10/14/2020 | Stephanie Vine

Most clinical trials against COVID-19 exclude the very patients most at risk from the disease.

Business & Regulation Standards & Regulation

Importation Action

10/13/2020 | Stephanie Vine

How will new guidance issued by the FDA affect drug importation?

Business & Regulation Business Practice

Harnessing Dark Data

10/24/2020 | Graeme Dennis

Graeme Dennis questions why the industry refuses to make use of the significant amount of data it generates.

Discovery & Development Drug Discovery

A Model Experiment

08/05/2020 | Audrey Dubourg

Harnessing the potential of microphysiological systems to advance drug discovery.

Manufacture Quality & Compliance

Zero Defects

08/10/2020 | Massimo Mainetti

Lives and livelihoods depend on accelerating large molecule drug production, so biopharma companies must minimize defects and contamination.

Focus on Quality – and the Rest Will Follow

09/29/2020 | Sponsored by Thermo Fisher Scientific

Amgen developed the Multi-Attribute Method (MAM) to obtain high-fidelity understanding of the quality of its own biologics. Click to read article

Business & Regulation Business Practice

Stemming the Brain Drain

10/22/2020 | Kelly Chibale

What can African nations do to retain the talent necessary for building pharmaceutical infrastructure?

Business & Regulation Business Practice

Why the African Medicines Agency’s Hour Has Arrived

10/21/2020 | Sarah Adam, Cyntia Genolet

Can the African Medicines Agency be mobilized quickly enough to respond to the needs of the pharmaceutical sector?

Business & Regulation Business Practice

Crisis Point

10/23/2020 | Maryam Mahdi

How is African pharma coping with the COVID-19 pandemic?

Manufacture Advanced Medicine

A Living Elixir?

10/19/2020 | James Strachan

Introducing the fourth therapeutic class: live biotherapeutics – microorganisms isolated from the human gut with the potential to treat many diseases.